Madiha Huq
Allergy · Southlake, TXNPI 1235638933
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,485 of the $4,599 with a category attached, or 75.8%. It is spread thinly across 22 manufacturers, the largest accounting for just 21.7% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for allergy clinicians in TX, where the typical reported total is $5,140.
Across 164 payments — averaging $28.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$1K
- AstraZeneca$918
- Amgen$371
- CSL Behring$351
- Regeneron Healthcare Solutions, Inc.$301
- ARS Pharmaceuticals Operations, Inc.$275
- plus $1K from 16 others
What the payments were for
- Grants$1,00022%
- Food & beverage$3,48576%
- Education$1142%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 1 | $1,000 |
| AstraZeneca | 28 | $918 |
| Amgen(2 entities) | 30 | $371 |
| CSL Behring | 17 | $351 |
| Regeneron Healthcare Solutions, Inc. | 12 | $301 |
| ARS Pharmaceuticals Operations, Inc. | 9 | $275 |
| GSK | 10 | $240 |
| Sanofi | 10 | $186 |
| AbbVie(2 entities) | 7 | $160 |
| Novartis | 6 | $123 |
| Kaleo, Inc. | 7 | $117 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $100 |
| Blueprint Medicines Corporation | 5 | $98 |
| Biocryst US Sales Co., LLC | 5 | $98 |
| Octapharma USA, Inc. | 3 | $82 |
| Sanofi-aventis U.S. LLC | 1 | $68 |
| Mylan Specialty L.p. | 2 | $36 |
| Hikma Pharmaceuticals USA | 1 | $17 |
| Merck | 1 | $16 |
| Pharming Healthcare, Inc. | 1 | $14 |
| Endo Pharmaceuticals Inc. | 1 | $14 |
| Jazz Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,599 in reported general payments places this provider in the 40th percentile of 69 allergy providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SymbicortBudesonide/Formoterol Fumarate | 11 | $2,604 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 14 | $2,018 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 17 | $329 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaSymbicort | $918 | $2,60411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 69 allergy providers in Texas.
Other allergy in Southlake
- Rene LeonSouthlake$48K
- Alireza ShakouriSouthlake$17K
- Gary GrossDallas$602K
- Christina HuddlestonDallas$26K
- Zachary MarshallRoanoke$17K
- Stuart AbramsonSan Angelo$16K
- Patricia DingerSan Antonio$15K
- Brian MillerGeorgetown$15K
- Carlos VitalHouston$14K
- David FuentesBoerne$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.